Nkarta Reports First Quarter 2021 Financial Results and Business Progress
May 13, 2021 16:02 ET
|
Nkarta, Inc.
NKX019 IND received FDA clearance; NKX019 patient dosing expected to start in 2H 2021Protocol amendment to ongoing NKX101 clinical trial adds a second multi-dosing regimen and a shorter waiting period...
Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies
April 28, 2021 08:02 ET
|
Nkarta, Inc.
NKX019 to be Nkarta’s second CAR NK pipeline program to enter clinical trial SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company...
Nkarta Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Business Progress
March 25, 2021 16:03 ET
|
Nkarta, Inc.
Continued progress in dosing of patients in clinical trial of NKX101, investigational CAR NK cell therapy engineered with NKG2D receptor, in acute myeloid leukemia (AML) and myelodysplastic syndrome...
Nkarta Announces February and March 2021 Investor Conference Schedule
February 17, 2021 16:03 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
Nkarta Reports Third Quarter 2020 Financial Results
November 12, 2020 16:03 ET
|
Nkarta, Inc.
First patient dosed in clinical trial of NKX101, investigational NK cell therapy engineered with NKG2D-targeted CAR, in acute myeloid leukemia and myelodysplastic syndromesIND application for NKX019...
Nkarta Announces Treatment of First Patient in First-in-Human Clinical Trial of Engineered NKG2D-Based NK Cell Cancer Immunotherapy NKX101
November 12, 2020 16:02 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
Nkarta Announces Presentation of Preclinical Data on NKX019, Engineered NK Cell Therapy Candidate Targeting CD19, at the Annual Meeting of the Society for Immunotherapy of Cancer
November 09, 2020 08:02 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
Nkarta Announces November & December 2020 Investor Conference Schedule
November 05, 2020 16:02 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
Nkarta Announces Leadership Changes
October 05, 2020 16:02 ET
|
Nkarta, Inc.
Nadir Mahmood, Ph.D. Named to Expanded Role as Chief Financial and Business OfficerAlicia J. Hager, J.D., Ph.D. to Join as Chief Legal Officer SOUTH SAN FRANCISCO, Calif., Oct. 05, 2020 (GLOBE...
Nkarta Announces October 2020 Investor Conference Schedule
September 29, 2020 08:02 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...